Partner Content Partner Content Superbugs: Exclusive Interviews Released with ABAC Therapeut... Q&A's Out Ahead of Superbugs 2018
Partner Content Partner Content Agenda released for SMi’s 20th Annual Superbugs European Sho... Agenda released for 20th Annual Superbugs Event
News Merck axes hepatitis C drug development Focus shifts to Keytruda amid competition from Gilead and shrinking market.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.